PT  - JOURNAL ARTICLE
AU  - David L. Longworth
TI  - Update on infectious disease prevention: Human papillomavirus, hepatitis A
DP  - 2008 Jun 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 402--410
VI  - 75
IP  - 6
4099  - http://www.ccjm.org/content/75/6/402.short
4100  - http://www.ccjm.org/content/75/6/402.full
SO  - Cleve Clin J Med2008 Jun 01; 75
AB  - Key studies on the prevention of human papillomavirus and hepatitis A published during the past year found that: A quadrivalent vaccine against human papillomavirus prevents cervical intraepithelial neoplasia, vulvar and vaginal intraepithelial neoplasia, and anogenital disease in young women. The vaccine is likely cost-effective when given to girls, but perhaps not when given to boys.Although hepatitis A immune globulin is modestly better than hepatitis A vaccine for postexposure prophylaxis against hepatitis A, both are highly effective. Hepatitis A vaccine is now recommended by the Advisory Committee on Immunization Practices as the preferred agent in healthy individuals between the ages of 2 and 40.